Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2020

19.04.2020 | Original Article

Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma

verfasst von: Alessandra Zecca, Valeria Barili, Diana Canetti, Valeria Regina, Andrea Olivani, Chiara Carone, Valentina Capizzuto, Barbara Zerbato, Tommaso Trenti, Raffaele Dalla Valle, Carlo Ferrari, Elisabetta Cariani, Gabriele Missale

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Functional rescue of NK-cells in solid tumors represents a central aim for new immunotherapeutic strategies. We have conducted a genomic, phenotypic and functional analysis of circulating NK-cells from patients with HCV-related liver cirrhosis and hepatocellular carcinoma. NK-cells were sorted from patients with HCC or liver cirrhosis and from healthy donors. Comparative mRNA gene expression profiling by whole-human-genome microarrays of sorted NK-cells was followed by phenotypic and functional characterization. To further identify possible mediators of NK-cell dysfunction, an in vitro model using media conditioned with patients’ and controls’ plasma was set up. Metabolic and cell motility defects were identified at the genomic level. Dysregulated gene expression profile has been translated into reduced cytokine production and degranulation despite a prevalent phenotype of terminally differentiated NK-cells. NKG2D-downregulation, high SMAD2 phosphorylation and other phenotypic and molecular alterations suggested TGF-β as possible mediator of this dysfunction. Blocking TGF-β could partially restore functional defects of NK-cells from healthy donors, exposed to TGF-β rich HCC patients’ plasma, suggesting that TGF-β among other molecules may represent a suitable target for immunotherapeutic intervention aimed at NK-cell functional restoration. By an unbiased approach, we have identified energy metabolism and cell motility defects of circulating NK-cells as main mechanisms responsible for functional NK-cell impairment in patients with hepatocellular carcinoma. This opens the way to test different approaches to restore NK-cell response in these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chiossone L, Dumas PY, Vienne M, Vivier E (2018) Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18:671–688CrossRef Chiossone L, Dumas PY, Vienne M, Vivier E (2018) Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18:671–688CrossRef
2.
Zurück zum Zitat Guillerey C, Chow MT, Miles K, Olver S, Sceneay J, Takeda K et al (2015) Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology 4:e1027468CrossRef Guillerey C, Chow MT, Miles K, Olver S, Sceneay J, Takeda K et al (2015) Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology 4:e1027468CrossRef
4.
Zurück zum Zitat Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477–491.e1CrossRef Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156:477–491.e1CrossRef
5.
Zurück zum Zitat Singal AG, El-Serag HB (2015) Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13:2140–2151CrossRef Singal AG, El-Serag HB (2015) Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13:2140–2151CrossRef
6.
Zurück zum Zitat Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83:58–63CrossRef Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83:58–63CrossRef
7.
Zurück zum Zitat Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799–807CrossRef Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799–807CrossRef
8.
Zurück zum Zitat Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S et al (2008) Functional impairment in circulating and intrahepatic NK-cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129:428–437CrossRef Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S et al (2008) Functional impairment in circulating and intrahepatic NK-cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129:428–437CrossRef
9.
Zurück zum Zitat Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, Li XF, Zheng L (2013) Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 57:1107–1116CrossRef Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, Li XF, Zheng L (2013) Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 57:1107–1116CrossRef
10.
Zurück zum Zitat Iñarrairaegui M, Melero I, Sangro B (2018) Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res 24:1518–1524CrossRef Iñarrairaegui M, Melero I, Sangro B (2018) Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res 24:1518–1524CrossRef
11.
Zurück zum Zitat Cariani E, Pilli M, Barili V, Porro E, Biasini E, Olivani A et al (2018) Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. Oncoimmunology 5:e1154249CrossRef Cariani E, Pilli M, Barili V, Porro E, Biasini E, Olivani A et al (2018) Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. Oncoimmunology 5:e1154249CrossRef
12.
Zurück zum Zitat Burshtyn BN, Shin J, Stebbins C, Long EO (2000) Adhesion to target cells is disrupted by killer cell inhibitory receptor. Curr Biol 10:700–780CrossRef Burshtyn BN, Shin J, Stebbins C, Long EO (2000) Adhesion to target cells is disrupted by killer cell inhibitory receptor. Curr Biol 10:700–780CrossRef
13.
Zurück zum Zitat Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M et al (2007) Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2:2719–2727CrossRef Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M et al (2007) Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2:2719–2727CrossRef
14.
Zurück zum Zitat Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180:7249–7258CrossRef Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180:7249–7258CrossRef
15.
Zurück zum Zitat Gardiner CM, Finlay DK (2017) What fuels natural killers? Metabolism and NK Cell responses. Front Immunol 8:367CrossRef Gardiner CM, Finlay DK (2017) What fuels natural killers? Metabolism and NK Cell responses. Front Immunol 8:367CrossRef
16.
Zurück zum Zitat Keating SE, Zaiatz-Bittencourt V, Loftus RM, Keane C, Brennan K, Finlay DK et al (2016) Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J Immunol 196:2552–2560CrossRef Keating SE, Zaiatz-Bittencourt V, Loftus RM, Keane C, Brennan K, Finlay DK et al (2016) Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J Immunol 196:2552–2560CrossRef
17.
Zurück zum Zitat Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE et al (2008) Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121–1128CrossRef Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE et al (2008) Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121–1128CrossRef
18.
Zurück zum Zitat Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H (2011) CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 133:350–359CrossRef Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H (2011) CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 133:350–359CrossRef
19.
Zurück zum Zitat Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X et al (2017) Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 14:819–829CrossRef Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X et al (2017) Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 14:819–829CrossRef
20.
Zurück zum Zitat Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T (2009) Maturation of mouse NK cells is a 4-stage developmental program. Blood 113:5488–5496CrossRef Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T (2009) Maturation of mouse NK cells is a 4-stage developmental program. Blood 113:5488–5496CrossRef
21.
Zurück zum Zitat Simonetta F, Pradier A, Roosnek E (2016) T-bet and eomesodermin in NK cell development, maturation, and function. Front Immunol 7:241CrossRef Simonetta F, Pradier A, Roosnek E (2016) T-bet and eomesodermin in NK cell development, maturation, and function. Front Immunol 7:241CrossRef
22.
Zurück zum Zitat Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK et al (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274–281CrossRef Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK et al (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274–281CrossRef
23.
Zurück zum Zitat Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K et al (2018) Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol 19:1330–1340CrossRef Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K et al (2018) Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol 19:1330–1340CrossRef
24.
Zurück zum Zitat Harmon C, Robinson MW, Hand F, Almuaili D, Mentor K, Houlihan DD et al (2019) Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res 7:335–346CrossRef Harmon C, Robinson MW, Hand F, Almuaili D, Mentor K, Houlihan DD et al (2019) Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res 7:335–346CrossRef
25.
Zurück zum Zitat Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni A et al (2019) Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma. Hepatology 69:1165–1179CrossRef Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni A et al (2019) Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma. Hepatology 69:1165–1179CrossRef
26.
Zurück zum Zitat Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y et al (2019) Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer 18:29CrossRef Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y et al (2019) Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer 18:29CrossRef
27.
Zurück zum Zitat Zaiatz-Bittencourt V, Finlay DK, Gardiner CM (2018) Canonical TGF-β signaling pathway represses human NK cell metabolism. J Immunol 200:3934–3941CrossRef Zaiatz-Bittencourt V, Finlay DK, Gardiner CM (2018) Canonical TGF-β signaling pathway represses human NK cell metabolism. J Immunol 200:3934–3941CrossRef
28.
Zurück zum Zitat Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F et al (2013) Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells. J Immunol 190:5321–5328CrossRef Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F et al (2013) Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells. J Immunol 190:5321–5328CrossRef
29.
Zurück zum Zitat Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K et al (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275–2279CrossRef Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K et al (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275–2279CrossRef
30.
Zurück zum Zitat Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O et al (2000) Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 12:811–814CrossRef Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O et al (2000) Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 12:811–814CrossRef
31.
Zurück zum Zitat Dituri F, Mancarella S, Cigliano A, Chieti A, Giannelli G (2019) TGF-β as multifaceted orchestrator in HCC progression: signaling, EMT, immune iicroenvironment, and novel therapeutic perspectives. Semin Liver Dis 39:53–69CrossRef Dituri F, Mancarella S, Cigliano A, Chieti A, Giannelli G (2019) TGF-β as multifaceted orchestrator in HCC progression: signaling, EMT, immune iicroenvironment, and novel therapeutic perspectives. Semin Liver Dis 39:53–69CrossRef
32.
Zurück zum Zitat Peng H, Tian Z (2017) Diversity of tissue-resident NK cells. SeminImmunol 31:3–10 Peng H, Tian Z (2017) Diversity of tissue-resident NK cells. SeminImmunol 31:3–10
33.
Zurück zum Zitat Easom NJW, Stegmann KA, Swadling L, Pallett LJ, Burton AR, Odera D et al (2018) IL-15 overcomes hepatocellular carcinoma-induced NK cell dysfunction. Front Immunol 9:1009CrossRef Easom NJW, Stegmann KA, Swadling L, Pallett LJ, Burton AR, Odera D et al (2018) IL-15 overcomes hepatocellular carcinoma-induced NK cell dysfunction. Front Immunol 9:1009CrossRef
Metadaten
Titel
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma
verfasst von
Alessandra Zecca
Valeria Barili
Diana Canetti
Valeria Regina
Andrea Olivani
Chiara Carone
Valentina Capizzuto
Barbara Zerbato
Tommaso Trenti
Raffaele Dalla Valle
Carlo Ferrari
Elisabetta Cariani
Gabriele Missale
Publikationsdatum
19.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02561-4

Weitere Artikel der Ausgabe 8/2020

Cancer Immunology, Immunotherapy 8/2020 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.